Sandbox Reserved 1646
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='7BR3' size='340' side='right' caption='PDB ID 7BR3' scene=''> | <StructureSection load='7BR3' size='340' side='right' caption='PDB ID 7BR3' scene=''> | ||
| - | It is a member of the seven-transmembrane, [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin like][https://en.wikipedia.org/wiki/G_protein-coupled_receptor G-protein coupled receptor (GPCR)] family<ref>DOI: 10.1210/edrv-15-4-462</ref> and is activated by the peptide hormone [https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone gonadotropin-releasing hormone (GnRH)] or the [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin like][https://proteopedia.org/wiki/index.php/4d5m synthetic agonist)]. The GnRHR is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate <ref>DOI: 10.1111/j.1742-4658.2008.06677.x</ref>. Its activity is critical for successful reproductive function. Several diseases are associated with a dysfunction of this receptor or the corresponding signaling cascade. | + | It is a member of the seven-transmembrane, [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin like][https://en.wikipedia.org/wiki/G_protein-coupled_receptor G-protein coupled receptor (GPCR)] family<ref>DOI: 10.1210/edrv-15-4-462</ref> and is activated by the peptide hormone [https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone gonadotropin-releasing hormone (GnRH)] or the [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin like][https://proteopedia.org/wiki/index.php/4d5m synthetic agonist)]. The GnRHR is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes, breast, ovary, and prostate<ref>DOI: 10.1111/j.1742-4658.2008.06677.x</ref>. Its activity is critical for successful reproductive function. Several diseases are associated with a dysfunction of this receptor or the corresponding signaling cascade. |
== Biological Function == | == Biological Function == | ||
| - | The gonadotropin-releasing hormone 1 receptor is located in the plasmic membrane of [https://en.wikipedia.org/wiki/Gonadotropic_cell pituitary gonadotrope cells] in the anterior pituitary, a major organ of the [https://en.wikipedia.org/wiki/Endocrine_system endocrine system] in the brain. It is activated by the [https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone gonadotropin-releasing hormone (GnRH)] which acts upon GnRHRs as the key regulator of puberty and reproduction. This peptide hormone is produced in the hypothalamus but gets secreted and acts upon GnRHRs in the anterior pituitary to exert its effects on reproductive maturation. The activation of the receptor, associates with G-proteins, leads to the releasing of [https://en.wikipedia.org/wiki/Luteinizing_hormone gonadotropic luteinizing hormone (LH)] and [https://en.wikipedia.org/wiki/Follicle-stimulating_hormone follicle-stimulating hormone (FSH)] by activating several signaling cascades. These pathways mainly correspond to the inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), MAPK, and adenyl cyclase pathways | + | The gonadotropin-releasing hormone 1 receptor is located in the plasmic membrane of [https://en.wikipedia.org/wiki/Gonadotropic_cell pituitary gonadotrope cells] in the anterior pituitary, a major organ of the [https://en.wikipedia.org/wiki/Endocrine_system endocrine system] in the brain. It is activated by the [https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone gonadotropin-releasing hormone (GnRH)] which acts upon GnRHRs as the key regulator of puberty and reproduction. This peptide hormone is produced in the hypothalamus but gets secreted and acts upon GnRHRs in the anterior pituitary to exert its effects on reproductive maturation. The activation of the receptor, associates with G-proteins, leads to the releasing of [https://en.wikipedia.org/wiki/Luteinizing_hormone gonadotropic luteinizing hormone (LH)] and [https://en.wikipedia.org/wiki/Follicle-stimulating_hormone follicle-stimulating hormone (FSH)] by activating several signaling cascades. These pathways mainly correspond to the inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), MAPK, and adenyl cyclase pathways<ref> DOI: 10.3892/or_00000525</ref>. |
==Structure == | ==Structure == | ||
| Line 13: | Line 13: | ||
=== General structure === | === General structure === | ||
| - | GnRH1R has the overall architecture of seven canonical transmembranes (TM) helices with connecting extra- and intracellular loop domains (ECL/ICL) similar to [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin-like receptors]. However, it lacks the typically occurring cytoplasmic C-terminal helix and has an unusual ligand binding mode. The structural variation between existing GnRHR Typ I, II, and III in different species has been analyzed <ref>DOI: 10.1210/er.2003-0002</ref>. First crystallographic structure analysis of human GnGH1R serves the investigation of the molecular mechanism of the receptor<ref>DOI: 10.1038/s41467-020-19109-w</ref>. In this analysis the GnRH1R contains certain modifications: ICL3 (aa 243-256) is replaced by the ''Pyrococcus abysi'' <scene name='86/868179/Abysi_glycogen_synthase/1'>glycogen synthase</scene>, it is in a complex with the [https://en.wikipedia.org/wiki/Receptor_antagonist antagonistic] drug <scene name='86/868179/Elagolix/4'>elagolix</scene>, and remains in inactive conformation in respect to [https://en.wikipedia.org/wiki/G_protein G protein] coupling. | + | GnRH1R has the overall architecture of seven canonical transmembranes (TM) helices with connecting extra- and intracellular loop domains (ECL/ICL) similar to [https://en.wikipedia.org/wiki/Rhodopsin-like_receptors rhodopsin-like receptors]. However, it lacks the typically occurring cytoplasmic C-terminal helix and has an unusual ligand binding mode. The structural variation between existing GnRHR Typ I, II, and III in different species has been analyzed<ref>DOI: 10.1210/er.2003-0002</ref>. First crystallographic structure analysis of human GnGH1R serves the investigation of the molecular mechanism of the receptor<ref>DOI: 10.1038/s41467-020-19109-w</ref>. In this analysis the GnRH1R contains certain modifications: ICL3 (aa 243-256) is replaced by the ''Pyrococcus abysi'' <scene name='86/868179/Abysi_glycogen_synthase/1'>glycogen synthase</scene>, it is in a complex with the [https://en.wikipedia.org/wiki/Receptor_antagonist antagonistic] drug <scene name='86/868179/Elagolix/4'>elagolix</scene>, and remains in inactive conformation in respect to [https://en.wikipedia.org/wiki/G_protein G protein] coupling. |
In this conformation, the ECL2 of GnRH1R forms an <scene name='86/868179/Beta-hairpin_structure/2'>extended β-hairpin</scene> and is anchored to the extracellular tip of TM3 through a conserved disulfide bond between residues C114 and C196. | In this conformation, the ECL2 of GnRH1R forms an <scene name='86/868179/Beta-hairpin_structure/2'>extended β-hairpin</scene> and is anchored to the extracellular tip of TM3 through a conserved disulfide bond between residues C114 and C196. | ||
Following structural highlights are different to receptors of this family: The well-known conserved D-R-Y motif is in fact the <scene name='86/868179/D-r-s_motif/2'>D138-R139-S140</scene> motif in GnRH1R. An intrahelical [https://en.wikipedia.org/wiki/Salt_bridge_(protein_and_supramolecular salt bridge] is observed between D138 and R139, as well as a polar interaction between R139 and T265 (This interaction restricts the outward movement of those TMs associated with GPCR activation). The <scene name='86/868179/N-terminus/6'>N-terminal region</scene> (aa 18–33) before TM1 is well folded and appears inserted into the orthostatic binding cavity. | Following structural highlights are different to receptors of this family: The well-known conserved D-R-Y motif is in fact the <scene name='86/868179/D-r-s_motif/2'>D138-R139-S140</scene> motif in GnRH1R. An intrahelical [https://en.wikipedia.org/wiki/Salt_bridge_(protein_and_supramolecular salt bridge] is observed between D138 and R139, as well as a polar interaction between R139 and T265 (This interaction restricts the outward movement of those TMs associated with GPCR activation). The <scene name='86/868179/N-terminus/6'>N-terminal region</scene> (aa 18–33) before TM1 is well folded and appears inserted into the orthostatic binding cavity. | ||
| Line 44: | Line 44: | ||
Like GnRH, peptide antagonists of the GnRH receptor are decapeptides, but with 50–70% of amino acids substituted, and they exhibit classical competitive antagonism ; | Like GnRH, peptide antagonists of the GnRH receptor are decapeptides, but with 50–70% of amino acids substituted, and they exhibit classical competitive antagonism ; | ||
Blockade of GnRH effects may be wanted for a variety of reasons—eg, to prevent untimely luteinization during assisted reproduction or in the treatment of sex-hormone-dependent disorders | Blockade of GnRH effects may be wanted for a variety of reasons—eg, to prevent untimely luteinization during assisted reproduction or in the treatment of sex-hormone-dependent disorders | ||
| - | Unlike the agonists, GnRH antagonists do not induce an initial stimulation of gonadotropin release but cause an immediate and rapid, reversible suppression of gonadotropin secretion. The principal mechanism of action of GnRH antagonists is competitive receptor occupancy of GnRH-r | + | Unlike the agonists, GnRH antagonists do not induce an initial stimulation of gonadotropin release but cause an immediate and rapid, reversible suppression of gonadotropin secretion. The principal mechanism of action of GnRH antagonists is competitive receptor occupancy of GnRH-r<ref>DOI: 10.1016/S0140-6736(01)06797-6</ref>. |
== Disease == | == Disease == | ||
| - | A mutation or dysfunction of the receptor could cause diseases impacting the reproduction function. More generally, the dysfunction of the pathways involving GnRH and its receptor leads to endocrine pathologies called [https://en.wikipedia.org/wiki/Hypogonadism hypogonadism] | + | A mutation or dysfunction of the receptor could cause diseases impacting the reproduction function. More generally, the dysfunction of the pathways involving GnRH and its receptor leads to endocrine pathologies called [https://en.wikipedia.org/wiki/Hypogonadism hypogonadism]<ref> DOI: 10.1016/j.cnur.2018.04.006</ref>. It exits many types of hypogonadism but the one involving the mutation of the receptor is the [https://en.wikipedia.org/wiki/Isolated_hypogonadotropic_hypogonadism idiopathic hypogonadotropic hypogonadism (IHH)]. In this case, the mutation leads to failure of detectable ligand binding causing the decreased efficiency of the inositol pathway and consequently leading to the decrease of the LH, FSH, and sex steroid secretions<ref>DOI 10.1210/jc.2003-031808</ref>. |
| - | Moreover, the activity of the pathways related to the receptor and its localization can cause cancer | + | Moreover, the activity of the pathways related to the receptor and its localization can cause cancer<ref>DOI: 10.1677/erc.1.00777</ref>. |
== Relevance == | == Relevance == | ||
| - | The main uses of the couple GnRH - GnRHR in the medical field is to cure hormone-dependent diseases and assisted reproductive techniques. For instance, an agonist of GnRH is used for fertility preservation as an alternative to cryopreservation <ref>DOI 10.1210/en.2013-1341</ref>. In addition it is a promising therapeutic target for the treatment of conditions including uterine fibroids <ref>DOI: 10.1080/17460441.2018.1417381</ref>, endometriosis <ref>DOI: 10.1080/14656566.2017.1359258</ref>, and prostate cancer <ref>DOI: 10.1002/pros.23360</ref>. | + | The main uses of the couple GnRH - GnRHR in the medical field is to cure hormone-dependent diseases and assisted reproductive techniques. For instance, an agonist of GnRH is used for fertility preservation as an alternative to cryopreservation<ref>DOI 10.1210/en.2013-1341</ref>. In addition it is a promising therapeutic target for the treatment of conditions including uterine fibroids<ref>DOI: 10.1080/17460441.2018.1417381</ref>, endometriosis <ref>DOI: 10.1080/14656566.2017.1359258</ref>, and prostate cancer<ref>DOI: 10.1002/pros.23360</ref>. |
| - | GnRH agonists and antagonists also have promise as novel contraceptives. Indeed, concerning animals, the GnRH receptor could be a good target for contraception with a DNA vaccine <ref>DOI: 10.1007/s12033-018-0137-9</ref> | + | GnRH agonists and antagonists also have promise as novel contraceptives. Indeed, concerning animals, the GnRH receptor could be a good target for contraception with a DNA vaccine<ref>DOI: 10.1007/s12033-018-0137-9</ref>. |
Besides, on pharmacological grounds, the primary indications for GnRH antagonists will be in any situation in which chemical gonadotropic hypophysectomy is required. | Besides, on pharmacological grounds, the primary indications for GnRH antagonists will be in any situation in which chemical gonadotropic hypophysectomy is required. | ||
Revision as of 12:44, 24 January 2021
| This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
Gonadotropin releasing hormone 1 receptor (GnRHR)
| |||||||||||
